METHODS: Totally 26 patients(44 eyes)with high myopia were enrolled in this research. The patients were all recieved ICL V4c implantation by the same surgeon in our hospital. The evaluation items included uncorrected visual acuity(UCVA), best corrected visual acuity(BCVA), intraocular pressure, corneal endothelial cell density(ECD), vault, objective scattering index(OSI), modulation transfer function cut off frequency(MTF cut off), Strehl ratio(SR), predicted visual acuity values(OV 100%, OV 20%, OV 9%)at contrasts of 100%, 20%and 9% and vision related quality of life questionnaire. All measurements were performed preoperative and 1wk, 1mo, 3mo postoperatively.

RESULTS: Compared with preoperative BCVA, for the high myopia patients, the 1wk, 1mo and 3mo UCVA postoperative were better at all time points, and the differences were statistically significant(P<0.001). Postoperative 1wk intraocular pressure was higher than that in preoperative and postoperative 1mo and 3mo(P<0.05). Postoperative corneal endothelial cell counts at all time points were lower than that in preoperative(P<0.05), but all within the normal range. No significant difference was found in vault(P=0.790). Compared with preoperative OSI, MTF cut off, SR, OV 100%, OV 20% and OV 9%, the situation improved at postoperative 1wk, 1mo and 3mo, with statistical significance(P<0.001). The vision related quality of life questionnaire showed that all patients had high satisfaction in the good subjective visual acuity after operation.

CONCLUSION: ICL V4c implantation is safe and effective in correcting high myopia. The objective visual quality and vision related quality of life of patients with high myopia was significantly improved after ICL V4c implantation in the early stage. The research laid a foundation for the establishment of “the comprehensive evaluation system of subjective and objective combination” of ICL in the application of high myopia.